VivoSeq
Metabolic & Endocrine

Overweight

0

Pipeline Programs↗

115

Active Trials↗

60

Companies Involved↗

Overweight is an early-stage landscape with 0 programs across 60 companies. The most active players are Novo Nordisk, Eli Lilly, Pfizer.

Intelligence

Pipeline Metrics

Competitive Density

61/100

Pipeline Velocity

74/100

Mech. Concentration

N/A

Completion Rate

91/100

Attrition Rate

5/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Novo Nordisk logo

Novo Nordisk

0 programs

PreclinicalEli Lilly logo

Eli Lilly

0 programs

PreclinicalPfizer logo

Pfizer

0 programs

PreclinicalBoehringer Ingelheim logo

Boehringer Ingelheim

0 programs

PreclinicalAstraZeneca logo

AstraZeneca

0 programs

PreclinicalO

Orexigen Therapeutics, Inc

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

382

clinical trials

Completed227 · 59%
Recruiting61 · 16%
Active, not recruiting30 · 8%
Not yet recruiting24 · 6%
Unknown status18 · 5%
Terminated14 · 4%
Other8 · 2%

Clinical Trials

Trial Activity

382 trials

The Efficacy and Safety of Efsubaglutide Alfa in Overweight/Obesity（SPARKLE）
Recruiting·SShanghai Yinnuo Pharmaceutical Technology Co., Ltd.·Phase 2·NCT07114419·200 enrolled
Effect of Vitamin D on Cardiovascular Metabolic Risk in Overweight/Obesity Adolescents in China
Recruiting·—·N/A·NCT07053657·130 enrolled
Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity
Recruiting·SStanford University·Phase 2·NCT05912621·66 enrolled
A Clincial Study Testing Tirzepatide on Reproductive Function and Metabolic Health in Women With PCOS Who Are Overweight or Obese
Recruiting·UUniversity of Bonn·Phase 4·NCT07326111·198 enrolled
Effect of Semaglutide on Embryo Quality in Overweight and Obese Patients Undergoing In Vitro Fertilization.
Recruiting·FFundacion Dexeus·Phase 4·NCT07242534·62 enrolled
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
Recruiting·Eli Lilly logoEli Lilly·Phase 3·NCT07232719·250 enrolled
A Study of SYNT-101 to Test Safety, Tolerability and Pharmacodynamics of SYNT-101 in Healthy and Overweight Adults
Recruiting·SSyntis Bio·Phase 1·NCT07307274·64 enrolled
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ZT003 Injection Following Single and Multiple Subcutaneous Administration in Healthy Volunteers/Overweight or Obese Volunteers
Recruiting·BBeijing QL Biopharmaceutical Co.,Ltd·Phase 1·NCT07184502·76 enrolled
The Safety, Tolerability, and Pharmacokinetics of of SYH9017 in Chinese Participants With Overweight and Obesity
Recruiting·CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.·Phase 1·NCT06830343·66 enrolled
Evaluation of RAY1225 in Adult Participants Who Have Obesity or Are Overweight
Recruiting·GGuangdong Raynovent Biotech Co., Ltd·Phase 3·NCT06893016·640 enrolled
Study of BMF-650 in Otherwise Healthy Overweight or Obese Adult Participants
Recruiting·BBiomea Fusion Inc.·Phase 1·NCT07223216·80 enrolled
A Clinical Study of Semaglutide Nasal Spray in Overweight or Obese Adults
Recruiting·SShanghai World Leader Pharmaceutical Co., Ltd.·Phase 1·NCT07465965·60 enrolled
Effect of LY3437943 Versus Placebo in Participants Who Have Obesity or Are Overweight
Recruiting·HHudson Biotech·Phase 2·NCT07467447·300 enrolled
A Study of BGM0504 Injection in Participants with Obesity or Overweight
Recruiting·BBrightGene New Bio-Medical Technology(Wuxi) Co.Ltd.·Phase 3·NCT06704581·620 enrolled
A Study in Healthy People or Otherwise Healthy With Overweight or Obesity to Compare 2 Formulations of Survodutide Given in Different Ways, Either as a Pre-filled Syringe or a Pen-like Injector
Recruiting·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 1·NCT07413913·56 enrolled
Page 1 of 26

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)